Dr. Silvia Deaglio is currently a Professor at the Department of Medical Sciences, University of Turin, Turin, Italy. After obtaining an MD degree and training as a medical oncologist, she enrolled in the PhD program in Genetics at the University of Turin, working on the role of the functional characterization of the CD38 gene family. From 2014 to 2016, she was a Visiting Associate Professor at Weill Cornell Medical College, to set up patient-derived xenograft models of CLL and Richter syndrome. In September 2016, she joined the Immunogenetics and Transplant Biology Unit of the Città della Salute e della Scienza University Hospital of Torino, intending to set up a diagnostic platform to provide genetic diagnosis and counseling to patients in need of an organ transplant with a suspected underlying monogenic disease and to patients with HLA-associated diseases. Her research interests are tumor microenvironment; tumor metabolism; cancer immune suppression; chronic lymphoid malignancies; and patient-derived xenografts.
Research Keywords & Expertise
tumor microenvironment
Tumor metabolism
Cancer immune suppress...
Chronic lymphoid malig...
Patient-derived xenogr...
Fingerprints
Patient-derived xenografts
tumor microenvironment
Short Biography
Dr. Silvia Deaglio is currently a Professor at the Department of Medical Sciences, University of Turin, Turin, Italy. After obtaining an MD degree and training as a medical oncologist, she enrolled in the PhD program in Genetics at the University of Turin, working on the role of the functional characterization of the CD38 gene family. From 2014 to 2016, she was a Visiting Associate Professor at Weill Cornell Medical College, to set up patient-derived xenograft models of CLL and Richter syndrome. In September 2016, she joined the Immunogenetics and Transplant Biology Unit of the Città della Salute e della Scienza University Hospital of Torino, intending to set up a diagnostic platform to provide genetic diagnosis and counseling to patients in need of an organ transplant with a suspected underlying monogenic disease and to patients with HLA-associated diseases. Her research interests are tumor microenvironment; tumor metabolism; cancer immune suppression; chronic lymphoid malignancies; and patient-derived xenografts.
